文献速递糖尿病肥胖与代谢综合征

糖尿病管理干预措施的成本效益:2008年以来的证据更新

Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008?
PubMed 文献 · Diabetes Care · 2020-01-01

该系统综述汇总了1985至2017年高收入国家122项研究,评估美国糖尿病协会(ADA)推荐干预措施的成本效益。结果显示,绝大多数ADA推荐干预措施仍具成本效益,其中ACEI/ARB强化降压、足部护理、远程视网膜筛查及减重手术等为节省成本;强化血糖管理、他汀治疗、糖尿病自我管理教育等为极具成本效益。

要点

  • ACEI/ARB强化降压、足部综合护理、远程视网膜筛查及减重手术节省成本。
  • 新诊断T2D强化血糖管理(A1C<7%)等11项干预极具成本效益。
  • 绝大多数ADA推荐干预措施仍具成本效益,可辅助资源优先配置。

核心结论

  • 绝大多数ADA推荐的糖尿病管理干预措施仍具有成本效益。

研究设计与样本

  • 对2008年6月至2017年7月发表的高收入国家研究进行系统综述,并纳入1985-2008年既往综述中的研究,共122项研究。

主要发现

  • 节省成本的干预包括:ACEI/ARB强化降压、ACEI/ARB预防白蛋白尿患者的CKD/ESRD、足部护理与患者教育、远程视网膜筛查、BMI≥30 kg/m²的T2D患者减重手术。
  • 极具成本效益的干预包括:新诊断T2D强化血糖管理(A1C<7%)、多组分干预、他汀治疗、糖尿病自我管理教育、每3年筛查T2D、整合式以患者为中心的护理、戒烟、每日阿司匹林一级预防、每日3次血糖自我监测、≥50岁T2D强化血糖管理、抑郁症协同护理。

关键数值与推荐

  • 成本效益阈值:节省成本(更多健康获益且成本更低)、极具成本效益(≤$25,000/LYG或QALY)、有成本效益($25,001-$50,000/LYG或QALY)、边际成本效益($50,001-$100,000/LYG或QALY)、无成本效益(>$100,000/LYG或QALY)。
  • 成本以2017年美元计。

临床怎么用

  • 临床医生和支付方可参考本综述对ADA推荐的干预措施进行优先级排序和医疗资源分配。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To synthesize updated evidence on the cost-effectiveness (CE) of interventions to manage diabetes, its complications, and comorbidities. RESEARCH DESIGN AND METHODS: We conducted a systematic literature review of studies from high-income countries evaluating the CE of diabetes management interventions recommended by the American Diabetes Association (ADA) and published in English between June 2008 and July 2017. We also incorporated studies from a previous CE review from the period 1985-2008. We classified the interventions based on their strength of evidence (strong, supportive, or uncertain) and levels of CE: cost-saving (more health benefit at a lower cost), very cost-effective (≤$25,000 per life year gained [LYG] or quality-adjusted life year [QALY]), cost-effective ($25,001-$50,000 per LYG or QALY), marginally cost-effective ($50,001-$100,000 per LYG or QALY), or not cost-effective (>$100,000 per LYG or QALY). Costs were measured in 2017 U.S. dollars. RESULTS: Seventy-three new studies met our inclusion criteria. These were combined with 49 studies from the previous review to yield 122 studies over the period 1985-2017. A large majority of the ADA-recommended interventions remain cost-effective. Specifically, we found strong evidence that the following ADA-recommended interventions are cost-saving or very cost-effective: In the cost-saving category are 1) ACE inhibitor (ACEI)/angiotensin receptor blocker (ARB) therapy for intensive hypertension management compared with standard hypertension management, 2) ACEI/ARB therapy to prevent chronic kidney disease and/or end-stage renal disease in people with albuminuria compared with no ACEI/ARB therapy, 3) comprehensive foot care and patient education to prevent and treat foot ulcers among those at moderate/high risk of developing foot ulcers, 4) telemedicine for diabetic retinopathy screening compared with office screening, and 5) bariatric surgery compared with no surgery for individuals with type 2 diabetes (T2D) and obesity (BMI ≥30 kg/m2). In the very cost-effective category are 1) intensive glycemic management (targeting A1C <7%) compared with conventional glycemic management (targeting an A1C level of 8-10%) for individuals with newly diagnosed T2D, 2) multicomponent interventions (involving behavior change/education and pharmacological therapy targeting hyperglycemia, hypertension, dyslipidemia, microalbuminuria, nephropathy/retinopathy, secondary prevention of cardiovascular disease with aspirin) compared with usual care, 3) statin therapy compared with no statin therapy for individuals with T2D and history of cardiovascular disease, 4) diabetes self-management education and support compared with usual care, 5) T2D screening every 3 years starting at age 45 years compared with no screening, 6) integrated, patient-centered care compared with usual care, 7) smoking cessation compared with no smoking cessation, 8) daily aspirin use as primary prevention for cardiovascular complications compared with usual care, 9) self-monitoring of blood glucose three times per day compared with once per day among those using insulin, 10) intensive glycemic management compared with conventional insulin therapy for T2D among adults aged ≥50 years, and 11) collaborative care for depression compared with usual care. CONCLUSIONS: Complementing professional treatment recommendations, our systematic review provides an updated understanding of the potential value of interventions to manage diabetes and its complications and can assist clinicians and payers in prioritizing interventions and health care resources.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Siegel KR, Ali MK, Zhou X, et al. Cost-effectiveness of Interventions to Manage Diabetes: Has the Evidence Changed Since 2008? Diabetes Care. 2020. PMID: 33534729. doi:10.2337/dci20-0017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。